Does anybody have a similar line of thought than I am, that this is just a different approach to trying to convince BARDA or some other public funding agency to get notice of NGIOs approach. Maybe they think that having a non profit organization such as LCFC decides for the II-key technology as their official approach, and pointing out this specific unmet need (again), may help to finally find a real donor to fund the related clinical trial.
Any think that way such as I do?
(3)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links